Evidence map›Paper›PMID 38928225›Full record

ArticleInternational journal of molecular sciences2024

Pseudolaric Acid B Targets CD147 to Selectively Kill Acute Myeloid Leukemia Cells.

Sheng Zou, Ekaterina Parfenova, Nikolina Vrdoljak, Mark D Minden, Paul A Spagnuolo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sheng ZouDepartment of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0009-0002-9190-0495
Ekaterina ParfenovaDepartment of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada.ORCID 0000-0001-7274-3397
Nikolina VrdoljakDepartment of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada.
Mark D MindenPrincess Margaret Cancer Center, Ontario Cancer Institute, Toronto, ON M5G 2M9, Canada.
Paul A SpagnuoloDepartment of Food Science, University of Guelph, Guelph, ON N1G 2W1, Canada.

Funding

University of Guelph GP
6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an aggressive blood cancer. With low survival rates, new drug targets are needed to improve treatment regimens and patient outcomes. Pseudolaric acid B (PAB) is a plant-derived bioactive compound predicted to interact with cluster of differentiation 147 (CD147/BSG). CD147 is a transmembrane glycoprotein overexpressed in various malignancies with suggested roles in regulating cancer cell survival, proliferation, invasion, and apoptosis. However, the detailed function of PAB in AML remains unknown. In this study, AML cell lines and patient-derived cells were used to show that PAB selectively targeted AML (IC50: 1.59 ± 0.47 µM). Moreover, proliferation assays, flow cytometry, and immunoblotting confirmed that PAB targeting of CD147 resulted in AML cell apoptosis. Indeed, the genetic silencing of CD147 significantly suppressed AML cell growth and attenuated PAB activity. Overall, PAB imparts anti-AML activity through transmembrane glycoprotein CD147.

Indexed as

ApoptosisBasiginCell ProliferationDiterpenesLeukemia, Myeloid, AcuteCell Line, TumorCell SurvivalHumansBasiginBSG protein, humanDiterpenespseudolaric acid Bacute myeloid leukemia (AML)apoptosisCD147 (EMMPRIN/BSG/BASIGIN)cell proliferationnuclear factor kB (NF-κB) pathwaypseudolaric acid B (PAB)

Identifiers

PMID38928225
PMCPMC11203802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.